Description
Encorafenib Medication
Braftovi (Encorafenib) is a kinase inhibitor used:
- together with binimetinib, to treat patients with unresectable/metastatic melanoma with a mutation named BRAF V600E or V600K.
- together with cetuximab, to treat adult patients with metastatic colorectal cancer (CRC) with a mutation named BRAF V600E, after prior therapy.
Dosage: The recommended dose of Braftovi (Encorafenib) for Melanoma is 450 mg orally taken once daily along with binimetinib. The recommended dose of Encorafenib for CRC is 300 mg orally once daily along with the drug cetuximab. Encorafenib may be administered either with or without food. Do not administer a missed encorafenib dose within 12 hours of the next dose of encorafenib. Do not take an additional dose in case vomiting occurs after encorafenib administration but continue with the next scheduled dose.
Side Effects: Melanoma: The most commonly reported encorafenib side effects along with binimetinib include:
- Fatigue
- Nausea
- Vomiting
- Abdominal pain
- Arthralgia
CRC: The most commonly reported side effects for encorafenib, along with cetuximab include:
- Rash
- Fatigue
- Nausea
- Diarrhea
- Abdominal pain
- Decreased appetite
- Arthralgia
- Dermatitis acneiform
Warnings and Precautions:
- Monitor patients with encorafenib 75 mg capsule for signs and symptoms of non-cutaneous malignancies.
- Patients with encorafenib dosage should be done for ophthalmologic evaluation at regular intervals and for any visual disturbances while on the therapy.
- Patients should be monitored for the electrolytes prior to and while on the braftovi 50 mg treatment.
- Monitor patients for malignancies and dermatologic evaluations should be done prior to, while on encorafenib fda label medication, and following interruption of therapy.
- Findings and mechanism of action of braftovi 75 mg suggest that this drug can cause fetal harm if administered to a pregnant woman.
- Advise women not to breastfeed while on treatment with encorafenib 50 mg and for 14 days after the final dose.
